Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.67 |
| ▸ | KMO | O15229 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.56 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.51 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.51 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.51 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.51 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5176875 | 0.86 | EPHX2 (0.55) | NAPRTKMOEPHX2PRMT6MKNK1 | |
| SCHEMBL2385420 | 0.83 | LMNA (0.67) | NAPRTKMOKDM4EMKNK1MKNK2 | |
| SCHEMBL3936298 | 0.83 | PRKCI (0.64) | NAPRTPRMT6GRIN2DGRIN3BGRIN1 | |
| SCHEMBL31338446 | 0.83 | LMNA (0.67) | NAPRTKMOKDM4EMKNK1MKNK2 | |
| SCHEMBL28032595 | 0.82 | LMNA (0.63) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3933089 | 0.82 | ALDH1A1 (0.60) | KMOKDM4EEPHX2PRMT6MKNK1 | |
| SCHEMBL538397 | 0.81 | ABCC4 (0.67) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL29430342 | 0.81 | NAPRT (1.00) | NAPRTKDM4EEPHX2CYP1A2CYP3A4 | |
| SCHEMBL48609 | 0.81 | NAPRT (1.00) | NAPRTKDM4EEPHX2CYP1A2CYP3A4 | |
| SCHEMBL13778475 | 0.80 | CYP11B1 (0.50) | NAPRTKDM4EGRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1819684-B1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | INTERVET INT BV (NL) | 2013-08-07 | — | — | EP | disclosed |
| US-8236805-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-8236805-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2012-08-07 | — | — | US | disclosed |
| US-7700597-B2 | Substituted piperazines as CB1 antagonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700597-B2 | Substituted piperazines as CB1 antagonists | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | SCHERING CORPORATION | 2010-02-04 | — | — | US | disclosed |
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | SCHERING CORPORATION | 2010-02-04 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| EP-2044017-A2 | SUBSTITUTED PHENYL ACETIC ACIDS AS DP-2 ANTAGONISTS | ICOS CORPORATION (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007146838-A2 | SUBSTITUTED PHENYL ACETIC ACIDS AS DP-2 ANTAGONISTS | ICOS CORPORATION (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007146838-A2 | SUBSTITUTED PHENYL ACETIC ACIDS AS DP-2 ANTAGONISTS | ICOS CORPORATION (US) | 2007-12-21 | — | — | WO | disclosed |
| CN-1255119-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2000-05-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029607-A1 | Substituted Piperazines as CB1 Antagonists | CNR1, CNR2, GPR119 | NAPRT 340/4885KMO 1067/4885KDM4E 2473/4885 |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | NAPRT 1081/4885KMO 667/4885KDM4E 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.